How the protein TAK1 may drive rhabdomyosarcoma growth
Official title: TAK1 signaling in Rhabdomyosarcoma tumorigenesis and growth
Funded at University of Houston · NIH-11258041 · Data updated 2026-11-12
This work tests whether blocking the protein TAK1 can stop rhabdomyosarcoma cells from growing and help them turn into normal muscle, with the goal of helping children and adults with RMS.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | February 1, 2025 |
| Project end | January 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $643,973 |
| NIH project number | 5R01CA294365-02 |
| Project ID | NIH-11258041 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with rhabdomyosarcoma (including alveolar and embryonal subtypes), both children and adults, would be the eventual patient group most likely to benefit from TAK1-targeted approaches.
✕Less likely to help
Patients without rhabdomyosarcoma or whose tumors do not rely on TAK1 signaling are unlikely to benefit directly from this work.
What this research studies
Researchers will study TAK1 activity in human rhabdomyosarcoma tumor samples and in laboratory-grown RMS cell lines to see how TAK1 affects cancer cell behavior. They will use genetic methods and drug-like inhibitors to block TAK1 and observe effects on tumor cell growth, cancer stem–like traits, and muscle differentiation. Promising findings will be tested in mouse xenograft models to see whether TAK1 inhibition slows tumor formation and promotes myogenic differentiation in living tissues. Overall, the project combines human samples, cell studies, and animal models to explore whether TAK1 is a useful target for future treatments.
Why it matters
Potential benefit: If successful, the work could identify TAK1 as a new therapeutic target that reduces tumor growth and promotes healthier muscle differentiation in rhabdomyosarcoma patients.
How similar studies have gone: Early preclinical data show TAK1 is active in RMS and that blocking it can reduce tumor-like traits in cells and mice, but clinical testing in patients has not yet been done.
Where this research is happening
-
University of Houston
Houston, United States Active
Researchers
- Principal investigator: Kumar, Ashok — University of Houston
- Study coordinator: Kumar, Ashok
Related research
Other NIH-funded projects on the same topics.
-
Targeting the PAX3-FOXO1 protein in a deadly childhood cancer
This study is looking at a specific protein that helps a tough childhood cancer called alveolar rhabdomyosarcoma, with the goal of finding new ways to treat kids who have this illness.
-
Targeting how RMS cells fail to mature to slow or stop pediatric muscle cancer spread
A project to understand why a pediatric muscle cancer called rhabdomyosarcoma spreads, and to test ideas that could slow or stop it by helping cancer cells mature properly.
-
Genetically engineered mouse model to study and treat high-risk pediatric rhabdomyosarcoma
A research project aims to create mouse models that mimic high-risk pediatric rhabdomyosarcoma and test therapies that target the NOTCH1 pathway to slow or stop tumor growth.
-
Understanding infantile rhabdomyosarcoma biology and new treatment targets
A new grant is studying why infantile rhabdomyosarcoma develops and what drugs or strategies could specifically target it in young children.
-
Targeting CLK2 to Fight Rhabdomyosarcoma
Aims to see if blocking CLK2 can weaken rhabdomyosarcoma cancer cells, potentially offering a new treatment for kids and young adults.
-
Epitranscriptomic Crosstalk in Alveolar Rhabdomyosarcoma
A pediatric cancer study that looks at how chemical marks on messenger RNA may influence the behavior of alveolar rhabdomyosarcoma and point toward newer treatment strategies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.